ScreenerHero

ADCT ADC Therapeutics SA

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · adctherapeutics.com
1.420USD+11.81%Mkt Cap: 181.29M $P/E: —

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap181.29M USD
Enterprise Value381.22M USD
Revenue (TTM)79.58M USD
Gross Profit75.56M USD
Net Income (TTM)-142.62M USD
Revenue/Share0.53 USD
Last Price1.420 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees188
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.85
PEG—
EV/EBITDA-4.07
EV/Revenue4.79
P/S2.04
P/B-0.71
EPS (TTM)-0.60
EPS (Forward)-1.49
52W Range
0.780015% of range4.980
52W High4.980 USD
52W Low0.7800 USD
Profitability
Gross Margin92.87%
Oper. Margin-118.14%
EBITDA Margin-117.75%
Profit Margin-175.31%
ROE76.75%
ROA-44.14%
Growth
Revenue Growth2.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-141.17M USD
CapEx (TTM)264.00K USD
FCF Margin-85.59%
FCF Yield-37.58%
Net Debt219.08M USD
Net Debt/EBITDA-2.34
Balance Sheet
Debt/Equity-0.63
Current Ratio3.03
Quick Ratio2.86
Book Value/Sh-1.79 USD
Cash/Share1.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.333 USD
Upside (mean)+134.7%
Target Range2.000 USD – 5.000 USD
2.000+134.7% to mean5.000
# Analysts3
Ownership
Shares Out.127.67M
Float88.56M
Insiders14.42%
Institutions67.56%
Short Interest
Short Ratio3.0d
Short % Float4.98%
Short % Out.4.22%
Shares Short5.39M
Short (prev mo.)6.18M
Technical
SMA 501.137 (+24.8%)
SMA 2002.678 (-47.0%)
Beta1.86
S&P 52W Chg15.78%
Avg Vol (30d)1.52M
Avg Vol (10d)1.30M
Technical Indicators
RSI (14)64.3
MACD0.0318
MACD Signal0.0161
MACD Hist.+0.0157
BB Upper1.392 USD
BB Middle1.180 USD
BB Lower0.9684 USD
BB Width35.86%
ATR (14)0.1034 USD
Vol Ratio (20d)1.22x